Financial Data and Key Metrics Changes - For the full year 2025, net revenues reached $175.1 million, reflecting a 217% year-over-year growth, with Q4 revenue at $57.6 million, consistent with pre-release estimates [8][16] - Cash operating expenses for Q4 were $50.3 million, better than the guidance of less than $55 million, and full-year cash operating expenses were approximately $284 million, at the low end of the range provided [9][18] - The company reported a loss from operations of approximately $320K in Q4, a 95% improvement compared to Q3 [17] Business Line Data and Key Metrics Changes - Voquezna prescriptions filled exceeded 1.1 million for over 230,000 patients, with Q4 alone accounting for 273,000 prescriptions, of which 174,000 were covered prescriptions, growing 21% quarter-over-quarter [12][14] - The sales organization is nearly fully staffed, with over 285 of 300 sales positions filled, indicating strong operational readiness [13][15] Market Data and Key Metrics Changes - The company targets a market of approximately 65 million patients suffering from gastroesophageal reflux, with 40% experiencing inadequate symptom relief from PPIs [12] - The gross margin remained consistent at approximately 87% for both Q4 and the full year [17] Company Strategy and Development Direction - The company aims to achieve operating profitability beginning in Q3 2026 and cash flow positivity in 2027, with a revenue guidance of $320 million-$345 million for 2026 [7][24] - The focus remains on enhancing the GI strategy and building relationships within the gastroenterology community to drive growth [14][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong momentum and a disciplined approach to expenses [11][26] - The company is not anticipating broad changes in Medicare coverage but is seeing incremental increases in Medicare prescriptions being covered [51] Other Important Information - The company successfully modified its term loan agreement, extending the maturity date to February 2029 and reducing the interest rate from 12% to 9.85% [19][20] - The company is exploring potential partnerships and additional product opportunities within the GI space, aiming to build a robust pipeline [81][82] Q&A Session Summary Question: Early signals from the strengthened sales force and strategy - Management noted consistent signs of momentum, with a high percentage of gastroenterologists already prescribing Voquezna and efforts focused on increasing writing frequency among existing prescribers [31][33] Question: Dynamics of patients transitioning back to primary care - Management acknowledged an uplift in primary care prescribing volume but emphasized the current focus on gastroenterology [39] Question: Expectations for Q1 sequential growth and Medicare coverage - Management indicated typical seasonality would impact Q1, and while there is no broad change in Medicare coverage anticipated, incremental coverage is being observed [46][51] Question: Proportions of prescriptions filled through GoodRx and BlinkRx - Management reported that over half of prescriptions are routed through BlinkRx, with a small percentage utilizing GoodRx for cash purchases [62] Question: Long-term vision beyond Voquezna - The company is focused on consolidating its execution plan for Voquezna while exploring additional GI assets for future growth [80][82]